# Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

> **NCT07405606** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Centre for Addiction and Mental Health** · enrollment: 30 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)
- Alcohol Use Disorder (AUD)

## Interventions

- **DRUG:** Psilocybin 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07405606
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-03
- **Final completion:** 2028-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07405606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07405606, "Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07405606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*